183 related articles for article (PubMed ID: 15907546)
1. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease.
Todd NV; Morrow J; Doh-ura K; Dealler S; O'Hare S; Farling P; Duddy M; Rainov NG
J Infect; 2005 Jun; 50(5):394-6. PubMed ID: 15907546
[TBL] [Abstract][Full Text] [Related]
2. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?
Rainov NG; Tsuboi Y; Krolak-Salmon P; Vighetto A; Doh-Ura K
Expert Opin Biol Ther; 2007 May; 7(5):713-26. PubMed ID: 17477808
[TBL] [Abstract][Full Text] [Related]
3. Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate.
Terada T; Tsuboi Y; Obi T; Doh-ura K; Murayama S; Kitamoto T; Yamada T; Mizoguchi K
Acta Neurol Scand; 2010 Feb; 121(2):127-30. PubMed ID: 19804470
[TBL] [Abstract][Full Text] [Related]
4. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease.
Whittle IR; Knight RS; Will RG
Acta Neurochir (Wien); 2006 Jun; 148(6):677-9; discussion 679. PubMed ID: 16598408
[TBL] [Abstract][Full Text] [Related]
5. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate.
Parry A; Baker I; Stacey R; Wimalaratna S
J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):733-4. PubMed ID: 17314188
[TBL] [Abstract][Full Text] [Related]
6. [Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Part II].
Zaborowski A
Psychiatr Pol; 2004; 38(2):297-309. PubMed ID: 15307294
[TBL] [Abstract][Full Text] [Related]
7. Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate.
Newman PK; Todd NV; Scoones D; Mead S; Knight RS; Will RG; Ironside JW
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):921-4. PubMed ID: 24554103
[TBL] [Abstract][Full Text] [Related]
8. Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion.
Honda H; Sasaki K; Minaki H; Masui K; Suzuki SO; Doh-Ura K; Iwaki T
Neuropathology; 2012 Apr; 32(2):124-32. PubMed ID: 21801238
[TBL] [Abstract][Full Text] [Related]
9. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases.
Tsuboi Y; Doh-Ura K; Yamada T
Neuropathology; 2009 Oct; 29(5):632-6. PubMed ID: 19788637
[TBL] [Abstract][Full Text] [Related]
10. [Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Part I].
Zaborowski A
Psychiatr Pol; 2004; 38(2):283-96. PubMed ID: 15307293
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A1 receptor protein levels and activity is increased in the cerebral cortex in Creutzfeldt-Jakob disease and in bovine spongiform encephalopathy-infected bovine-PrP mice.
Rodríguez A; Martín M; Albasanz JL; Barrachina M; Espinosa JC; Torres JM; Ferrer I
J Neuropathol Exp Neurol; 2006 Oct; 65(10):964-75. PubMed ID: 17021401
[TBL] [Abstract][Full Text] [Related]
12. Experimental treatment may show promise for vCJD.
Pincock S
Lancet; 2003 Oct; 362(9390):1130. PubMed ID: 14558510
[No Abstract] [Full Text] [Related]
13. [New knowledge about Creutzfeldt-Jakob disease can yield therapeutic possibilities].
Stølsmark T; Tysnes OB
Tidsskr Nor Laegeforen; 2010 Mar; 130(6):601-4. PubMed ID: 20349004
[TBL] [Abstract][Full Text] [Related]
14. Altered properties of amyloidogenic prion protein in genetic Creutzfeldt-Jakob disease with PRNP V180I mutation in response to pentosan polysulfate.
Shijo M; Yoshimura M; Omae T; Hashimoto G; Mizoguchi T; Kuwashiro T; Komori T; Tsuboi Y; Saito T; Nakagawa M; Itoh K; Honda H
Brain Pathol; 2023 Sep; 33(5):e13197. PubMed ID: 37525413
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies.
Farquhar C; Dickinson A; Bruce M
Lancet; 1999 Jan; 353(9147):117. PubMed ID: 10023899
[No Abstract] [Full Text] [Related]
16. BSE and vCJD cause disturbance to uric acid levels.
Lekishvili T; Sassoon J; Thompsett AR; Green A; Ironside JW; Brown DR
Exp Neurol; 2004 Nov; 190(1):233-44. PubMed ID: 15473996
[TBL] [Abstract][Full Text] [Related]
17. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models.
Doh-ura K; Ishikawa K; Murakami-Kubo I; Sasaki K; Mohri S; Race R; Iwaki T
J Virol; 2004 May; 78(10):4999-5006. PubMed ID: 15113880
[TBL] [Abstract][Full Text] [Related]
18. PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease.
Herzog C; Rivière J; Lescoutra-Etchegaray N; Charbonnier A; Leblanc V; Salès N; Deslys JP; Lasmézas CI
J Virol; 2005 Nov; 79(22):14339-45. PubMed ID: 16254368
[TBL] [Abstract][Full Text] [Related]
19. Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease.
Dealler S; Rainov NG
IDrugs; 2003 May; 6(5):470-8. PubMed ID: 12789602
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of water channel aquaporin 1 and aquaporin 4 in Creutzfeldt-Jakob disease and in bovine spongiform encephalopathy-infected bovine-PrP transgenic mice.
Rodríguez A; Pérez-Gracia E; Espinosa JC; Pumarola M; Torres JM; Ferrer I
Acta Neuropathol; 2006 Nov; 112(5):573-85. PubMed ID: 16871401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
